Company intelligence

NGNE

Neurogene Inc. · NASDAQ · Healthcare

Price$40.84+3.03% · +$1.20

Market cap645.37MEquity value

P / E-9.0Trailing ratio

Volume504.33KLatest session

Market data

NGNE price chart

TradingView

Related signals

1 min delayed

Browse public NGNE signals with their source context and measured market impact. Open any signal for its permanent analysis page.

NGNENov 18, 2024-18.57% since signal

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Neurogene halted its high-dose gene therapy trial due to an adverse event. NGNE shares plunged 37.7% to $21.50 in pre-market trading. Other stocks also experienced declines in pre-market trading. Overall market futures were mixed, indicating market volatility.

View signal analysis

NGNENov 12, 2024-1.86% since signal

Neurogene Stock Tanks After Adverse Event In Early-Stage Rett Syndrome Gene Therapy Trial

Neurogene's NGN-401 shows favorable safety in pediatric Rett syndrome trial. All low-dose participants reported significant clinical improvement on CGII scale. NGNE stock dropped 44% following trial data release. Adolescent/adult cohort initiated for broader NGN-401 data. NGNE will not advance NGN-101 for Batten disease.

View signal analysis

Research